# KMT2D
## Overview
KMT2D (also known as MLL2) encodes a histone H3K4 methyltransferase, playing a crucial role in germinal center B cell development and function. Mutations in KMT2D are among the most common mutations in FL and are also common in DLBCL.<sup>1</sup> KMT2D mutations are recurrent but less common in BL and MCL and many other B-cell neoplasms. Mutations typically cause loss of KMT2D function, leading to diminished H3K4 methylation, impacting gene expression that favours lymphomagenesis. KMT2D mutations are associated with poor prognosis in DLBCL.<sup>2,3</sup>

## Relevance tier by entity

|Entity|Tier|Description               |
|:------:|:----:|--------------------------|
|FL    |1   |high-confidence FL gene   |
|DLBCL |1   |high-confidence DLBCL gene|
|BL    |1   |high-confidence BL gene   |
|MCL   |1   |high-confidence MCL gene  |

## Mutation incidence in large patient cohorts (GAMBL reanalysis)

|Entity|source               |frequency (%)|
|:------:|:---------------------:|:-------------:|
|FL    |GAMBL genomes        |67.67        |
|DLBCL |GAMBL genomes        |33.46        |
|DLBCL |Schmitz cohort       |34.47        |
|DLBCL |Reddy cohort         |22.32        |
|DLBCL |Chapuy cohort        |26.07        |
|BL    |GAMBL genomes+capture|11.32        |
|BL    |Thomas cohort        |14.00        |
|BL    |Panea cohort         |15.80        |
|MCL   |GAMBL genomes        |16.59        |

## Mutation pattern and selective pressure estimates

|Entity|aSHM|Significant selection|dN/dS (missense)|dN/dS (nonsense)|
|:------:|:----:|:---------------------:|:----------------:|:----------------:|
|BL    |No  |Yes                  | 0.689          |  13.459        |
|DLBCL |No  |Yes                  | 3.731          | 104.190        |
|FL    |No  |Yes                  |20.755          |1353.812        |


> [!NOTE]
> First described in BL in 2019 by [Grande BM](https://pubmed.ncbi.nlm.nih.gov/30617194). First described in DLBCL in 2011 by [Morin RD](https://pubmed.ncbi.nlm.nih.gov/21796119). First described in FL in 2011 by [Morin RD](https://pubmed.ncbi.nlm.nih.gov/21796119). First described in MCL in 2013 by [Beà S](https://pubmed.ncbi.nlm.nih.gov/24145436)


View coding variants in ProteinPaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/KMT2D_protein.html)  or [hg38](https://morinlab.github.io/LLMPP/GAMBL/KMT2D_protein_hg38.html)

![image](images/proteinpaint/KMT2D_NM_003482.svg)

View all variants in GenomePaint [hg19](https://morinlab.github.io/LLMPP/GAMBL/KMT2D.html)  or [hg38](https://morinlab.github.io/LLMPP/GAMBL/KMT2D_hg38.html)

![image](images/proteinpaint/KMT2D.svg)

## References
1. *Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme MR, Rogic S, Griffith M, Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus D, Moksa M, Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ, Ben-Neriah S, Meissner B, Woolcock B, Boyle M, McDonald H, Tam A, Zhao Y, Delaney A, Zeng T, Tse K, Butterfield Y, Birol I, Holt R, Schein J, Horsman DE, Moore R, Jones SJ, Connors JM, Hirst M, Gascoyne RD, Marra MA. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011 Jul 27;476(7360):298-303. doi: 10.1038/nature10351. PMID: 21796119; PMCID: PMC3210554.*
2. *You, H., Xu-Monette, Z., Wei, L., Nunns, H., Nagy, M., Bhagat, G., Fang, X., Zhu, F., Visco, C., Tzankov, A., Dybkaer, K., Chiu, A., Tam, W., Zu, Y., Hsi, E., Hagemeister, F., Huh, J., Ponzoni, M., Ferreri, A., Møller, M., Parsons, B., Krieken, J., Piris, M., Winter, J., Li, Y., Au, Q., Xu, B., Albitar, M., & Young, K. (2021). Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma. Oncoimmunology, 10. https://doi.org/10.1080/2162402X.2021.1928365.*
3. *Rushton CK, Arthur SE, Alcaide M, Cheung M, Jiang A, Coyle KM, Cleary KLS, Thomas N, Hilton LK, Michaud N, Daigle S, Davidson J, Bushell K, Yu S, Rys RN, Jain M, Shepherd L, Marra MA, Kuruvilla J, Crump M, Mann K, Assouline S, Connors JM, Steidl C, Cragg MS, Scott DW, Johnson NA, Morin RD. Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma. Blood Adv. 2020 Jul 14;4(13):2886-2898. doi: 10.1182/bloodadvances.2020001696. PMID: 32589730; PMCID: PMC7362366.*
## KMT2D Expression
![image](images/gene_expression/KMT2D_by_pathology.svg)
